Hemab Therapeutics raised $157 million in a financing round to advance a pipeline focused on underserved bleeding disorders. The funding, led by Sofinnova Partners and including Novo Holdings and crossover investors, will support pivotal plans for sutacimig in Glanzmann thrombasthenia and continued development of HMB‑002 and other programs. Hemab said one candidate will enter a pivotal trial next year while others remain in early clinical evaluation after proof‑of‑mechanism signals. Management framed the cash as building “the ultimate coagulation disorders company” to tackle conditions historically neglected due to small markets and technical complexity. The round underscores renewed investor appetite for specialty hematology and replacement/antibody approaches to clotting diseases; competitors working on von Willebrand disease and Factor VII deficiency may face new comparative data and partnership dynamics as Hemab advances.